Environmental, Social, and Governance (ESG)

Building a Responsible Future in Pharma

At MMS, our commitment to excellence extends beyond drug development. As an award-winning, data-focused CRO, we recognize our responsibility to contribute to a sustainable, ethical, and socially responsible future. Our ESG strategy is integral to our mission to positively improve patient’s lives globally, and it guides us in every aspect of our operations and partnerships.

Environmental Responsibility

We are dedicated to minimizing the environmental footprint of MMS and promoting sustainable practices across all our operations around the world. We proactively seek to reduce energy consumption, manage waste responsibly, and support environmental initiatives internally and in the communities where we live and work.

By leveraging technology and data-driven solutions, we optimize our processes to ensure efficiency and sustainability, including:

  • Green Facilities: We are committed to maintaining eco-friendly offices, implementing energy-saving methodologies and technologies, as well as reducing our reliance on non-renewable resources.
  • Sustainable Operations: Through continuous monitoring and assessment, we identify areas where MMS colleagues can reduce waste, recycle materials, and minimize our impact on the environment.
  • Collaborative Initiatives: We partner with like-minded organizations to advance environmental sustainability in clinical research, aiming for a higher standard.
Social Impact

Our success is intertwined with the well-being of the communities we serve and the experts that we employ. MMS fosters an inclusive and supportive workplace to drive positive change for individual stakeholders, partners, sponsors, and ultimately the public through the outcomes from our work.

This includes the following:

  • Diversity, Equity, and Inclusion: MMS is committed to maintaining a diverse and inclusive environment where all employees feel valued and empowered to contribute their best. Our DEI initiatives are embedded in our recruitment, training, and continuous leadership development programs.
  • Community Engagement: We actively engage with the local communities that we operate in, through individual and company-led volunteer efforts and other initiatives. Our team members are given time during the workday to volunteer and MMS provides resources to amplify their impact.
  • Patient-Centric Outcomes: Our work with sponsors prioritizes patient safety, transparency, and accessibility. We strive to ensure that our support of drug development programs across nearly all therapeutic areas maintain high ethical and scientific standards, allowing the results to have a meaningful contribution to public health.
Governance Excellence

MMS is guided by a strong governance framework that ensures clarity and accountability at all levels of the organization globally. Our governance practices are designed to protect the interests of our stakeholders, including:

  • Ethical Standards: We adhere to the highest ethical standards across all projects and business practices. This ensures that all activities are conducted with integrity and respect for the regulatory requirements set by global health authorities.
  • Transparent Reporting: We are committed to providing clear and accurate reporting on our ESG initiatives, demonstrating our progress and areas for improvement. This allows us to build further trust with our stakeholders and reinforce our commitment to accountability.
  • Continuous Improvement: Our governance framework is dynamic, changing as pharmaceutical industry best practices evolve and stakeholder expectations heighten. We regularly review and enhance our policies and procedures to ensure they align with our ESG goals.
Our Commitment

MMS is proud to be at the forefront of integrating ESG principles into our #OneMMS ecosystem. We understand that our work has a far-reaching impact. This motivates every decision that we make, and we are dedicated to making a positive difference in the world.

By prioritizing sustainability, social responsibility, and strong governance, we are building a future that benefits all. Join MMS on our journey and message us with any questions that you may have.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization